Stocks · News reference
Medicus Pharma Says CD228V ADC Now Principal Strategic Priority, With Initial Development In Relapsed Or Refractory Melanoma; Says FDA Authorized Initiation Of Registrational Phase 2b SkinJect Study In Gorlin Syndrome
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Medicus Pharma Inks Global Licensing Deal with Pfizer Worth Over $1 Billion
Medicus Pharma partners with Pfizer to commercialize CD228V in a licensing deal worth over $1 billion plus royalties.
Nasdaq Gains Over 200 Points; US Weekly Jobless Claims Edge Higher
U.S. stocks climbed, led by Nasdaq; communications shares rose, energy fell, while MIMI surged and RARE plunged after trial failures.